



CIRRUSDX

FINAL

Accession #: W2025-000652

Name: Clark, Betty

DOB: 7/5/1973

MRN/SSN:

Sex: Female

Laboratory Information	Sample Information	Practice Information
CirrusDx, Inc 77 Upper Rock Circle, 4 th Floor Rockville, MD 20850 CLIA# 21D2130541 Dr. Todd Myers, Lab Director 240-813-8801 or reports@cirusdx.com	Technician: CWS Date Collected: 12/1/2025 Date Received: 12/2/2025 Date Reported: 12/2/2025 Reporting Method: Email	Name: Podiatry and Wound Care Provider: Winesap MD, Roma Address: 3464 Salarian St. Garrus MS 98765 Phone: 301-555-5555 Fax: 240-555-5555 Email: results@pwc.com

Test Information: Wound Infection Panel (WIP™) & Culture Based AST (polyMIC™)				
Specimen Type:	Wound Swab	Right Foot	Antibiotic Usage:	None

Detected pathogens, as determined by Wound Infection Panel (WIP™)		
Organism Name	Classification	Detection Level (Organism/mL)
Not Detected	N/A	N/A

General Comments
Antibiotic susceptibility not performed; no organisms detected in Wound Infection Panel (WIP™).



CIRRUSDX

FINAL

Accession #: W2025-000652

Name: Clark, Betty

DOB: 7/5/1973

MRN/SSN:

Sex: Female

Notes:

Questions including Clinical Consultation on Results: 240-813-8801 or reports@cirusdx.com

Organism Tested (Reference Range):

Organism List	
Reference Range is listed next to each organism	
Acinetobacter baumannii < 1x10 ³	Klebsiella oxytoca < 1x10 ⁴
Anaerococcus spp. (A. vaginalis)* < 1x10 ⁴	Klebsiella pneumoniae < 1x10 ⁴
Bacteroides fragilis < 1x10 ³	Methicillin Resistance (mecA/mecC) Not Detected
Candida spp. (C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis) < 1x10 ³	MRSA (Methicillin-resistant Staphylococcus aureus) < 1x10 ⁴
Citrobacter spp. (C. koseri and C. freundii) < 1x10 ³	Peptostreptococcus spp. (P. anaerobius)* < 1x10 ⁴
Clostridium spp. (C. perfringens and C. septicum)* < 1x10 ⁴	Porphyromonas spp. (P. gingivalis)* < 1x10 ³
CNS - Coagulase Negative Staphylococcus (S. epidermidis, S. haemolyticus, S. lugdunensis, S. saprophyticus) < 1x10 ⁴	Prevotella bivia < 1x10 ⁴
Corynebacterium spp. (C. tuberculostearicum and C. jeikeium)* < 1x10 ³	Proteus spp. (P. mirabilis and P. vulgaris) < 1x10 ⁴
Cutibacterium spp. (C. acnes)* < 1x10 ⁴	Pseudomonas aeruginosa < 1x10 ⁴
Enterobacter cloacae < 1x10 ³	Serratia marcescens < 1x10 ⁴
Enterococcus faecalis < 1x10 ⁴	Staphylococcus aureus < 1x10 ³
Enterococcus faecium < 1x10 ⁴	Stenotrophomonas maltophilia < 1x10 ⁴
Escherichia coli < 1x10 ³	Streptococcus agalactiae < 1x10 ⁴
Finegoldia magna < 1x10 ³	Streptococcus pyogenes < 1x10 ⁴
Klebsiella aerogenes < 1x10 ⁴	Viridans Group Streptococci (S. mitis, S. pneumoniae, S. parasanguinis, S. sanguinis)* < 1x10 ⁴

*Due to the complexity of the bacteria genus, there may be other species that are detected in the assay that are not listed.

Organisms/ml: are based on the calculation of genome equivalents. One genome equivalent is theoretically equal to one colony forming unit (cfu).**WIP™ test method:** Wound Infection Panel, Real-Time PCR.**polyMIC™ test method:** Antibiotic susceptibility testing is performed by using culture. Reference range for antibiotics are susceptible.**Hal (H):** is the result of both Sensitive and Resistant organisms responding to an antibiotic.**Sensitive (S):** indicates the organism(s) is susceptible to the antibiotic.**Intermediate (I):** indicates the organism(s) is susceptible to the antibiotic but not at a level required to ensure effectiveness.**Resistant (R):** indicates the organism(s) is not susceptible (resistant).**Intrinsic Resistance (iR):** bacterium is known to be intrinsically resistant to this antibiotic.**Black Spaces in polyMIC™ Tables:** are there for the following reasons: the antibiotic was not cleared by the FDA for use with that bacterium, there is insufficient evidence in the literature to support using that antibiotic for that bacterium, and/or that antibiotic has been shown in the literature to not be effective against that bacterium. Laboratory susceptibility does not always predict clinical outcomes.

It is the physician's responsibility to interpret the results provided and determine the appropriate (if any) treatment options including antibiotic selection.

The assays were developed and their performance characteristics were determined by CirrusDx. They have not been cleared or approved by the US Food and Drug Administration. The FDA does not require these tests to go through premarket FDA review. This test is used for clinical purposes. It should not be regarded as investigational or for research.

This report has been reviewed and approved by:

Dr. Todd Myers, Laboratory Director.

F-270.05